192 related articles for article (PubMed ID: 21853157)
41. A novel MPL point mutation resulting in thrombopoietin-independent activation.
Abe M; Suzuki K; Inagaki O; Sassa S; Shikama H
Leukemia; 2002 Aug; 16(8):1500-6. PubMed ID: 12145691
[TBL] [Abstract][Full Text] [Related]
42. The induction of megakaryocyte differentiation is accompanied by selective Ser133 phosphorylation of the transcription factor CREB in both HEL cell line and primary CD34+ cells.
Zauli G; Gibellini D; Vitale M; Secchiero P; Celeghini C; Bassini A; Pierpaoli S; Marchisio M; Guidotti L; Capitani S
Blood; 1998 Jul; 92(2):472-80. PubMed ID: 9657746
[TBL] [Abstract][Full Text] [Related]
43. Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.
Okabe S; Tauchi T; Katagiri S; Tanaka Y; Ohyashiki K
J Hematol Oncol; 2014 Apr; 7():37. PubMed ID: 24775308
[TBL] [Abstract][Full Text] [Related]
44. Simultaneous signalling through c-mpl, c-kit and CXCR4 enhances the proliferation and differentiation of human megakaryocyte progenitors: possible roles of the PI3-K, PKC and MAPK pathways.
Minamiguchi H; Kimura T; Urata Y; Miyazaki H; Bamba T; Abe T; Sonoda Y
Br J Haematol; 2001 Oct; 115(1):175-85. PubMed ID: 11722431
[TBL] [Abstract][Full Text] [Related]
45. Thrombopoietin suppresses apoptosis and behaves as a survival factor for the human growth factor-dependent cell line, M07e.
Ritchie A; Vadhan-Raj S; Broxmeyer HE
Stem Cells; 1996 May; 14(3):330-6. PubMed ID: 8724699
[TBL] [Abstract][Full Text] [Related]
46. Distinct effects of thrombopoietin depending on a threshold level of activated Mpl in BaF-3 cells.
Millot GA; Vainchenker W; Duménil D; Svinarchuk F
J Cell Sci; 2002 Jun; 115(Pt 11):2329-37. PubMed ID: 12006617
[TBL] [Abstract][Full Text] [Related]
47. [Role of LNK gene mutation in pathogenesis of myeloproliferative neoplasms-review].
Chen Y; Wu XQ; Han CS; Zhu P; Wei JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1309-12. PubMed ID: 24156456
[TBL] [Abstract][Full Text] [Related]
48. Specific association of a set of molecular chaperones including HSP90 and Cdc37 with MOK, a member of the mitogen-activated protein kinase superfamily.
Miyata Y; Ikawa Y; Shibuya M; Nishida E
J Biol Chem; 2001 Jun; 276(24):21841-8. PubMed ID: 11278794
[TBL] [Abstract][Full Text] [Related]
49. Use of human leukemia-lymphoma cell lines in hematological research: effects of thrombopoietin on human leukemia cell lines.
Drexler HG; Quentmeier H
Hum Cell; 1996 Dec; 9(4):309-16. PubMed ID: 9183663
[TBL] [Abstract][Full Text] [Related]
50. Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway.
Rouyez MC; Boucheron C; Gisselbrecht S; Dusanter-Fourt I; Porteu F
Mol Cell Biol; 1997 Sep; 17(9):4991-5000. PubMed ID: 9271377
[TBL] [Abstract][Full Text] [Related]
51. Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling.
Louria-Hayon I; Frelin C; Ruston J; Gish G; Jin J; Kofler MM; Lambert JP; Adissu HA; Milyavsky M; Herrington R; Minden MD; Dick JE; Gingras AC; Iscove NN; Pawson T
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20599-604. PubMed ID: 24297922
[TBL] [Abstract][Full Text] [Related]
52. Lyn tyrosine kinase regulates thrombopoietin-induced proliferation of hematopoietic cell lines and primary megakaryocytic progenitors.
Lannutti BJ; Drachman JG
Blood; 2004 May; 103(10):3736-43. PubMed ID: 14726379
[TBL] [Abstract][Full Text] [Related]
53. Adaptor protein Lnk inhibits c-Fms-mediated macrophage function.
Gueller S; Goodridge HS; Niebuhr B; Xing H; Koren-Michowitz M; Serve H; Underhill DM; Brandts CH; Koeffler HP
J Leukoc Biol; 2010 Oct; 88(4):699-706. PubMed ID: 20571037
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of erythroid differentiation and induction of megakaryocytic differentiation by thrombopoietin are regulated by two different mechanisms in TPO-dependent UT-7/c-mpl and TF-1/c-mpl cell lines.
Goncalves F; Lacout C; Féger F; Cohen-Solal K; Guichard J; Cramer E; Vainchenker W; Duménil D
Leukemia; 1998 Sep; 12(9):1355-66. PubMed ID: 9737683
[TBL] [Abstract][Full Text] [Related]
55. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
[TBL] [Abstract][Full Text] [Related]
56. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3.
Yang F; Brown C; Buettner R; Hedvat M; Starr R; Scuto A; Schroeder A; Jensen M; Jove R
Mol Cancer Ther; 2010 Apr; 9(4):953-62. PubMed ID: 20371721
[TBL] [Abstract][Full Text] [Related]
57. Thrombopoietin: expression of its receptor MPL and proliferative effects on leukemic cells.
Drexler HG; Quentmeier H
Leukemia; 1996 Sep; 10(9):1405-21. PubMed ID: 8751457
[TBL] [Abstract][Full Text] [Related]
58. LNK (SH2B3): paradoxical effects in ovarian cancer.
Ding LW; Sun QY; Lin DC; Chien W; Hattori N; Dong XM; Gery S; Garg M; Doan NB; Said JW; Xiao JF; Yang H; Liu LZ; Meng X; Huang RY; Tang K; Koeffler HP
Oncogene; 2015 Mar; 34(11):1463-74. PubMed ID: 24704825
[TBL] [Abstract][Full Text] [Related]
59. Expression of the GPI-anchored receptor Prv-1 enhances thrombopoietin and IL-3-induced proliferation in hematopoietic cell lines.
Dillon M; Minear J; Johnson J; Lannutti BJ
Leuk Res; 2008 May; 32(5):811-9. PubMed ID: 17980909
[TBL] [Abstract][Full Text] [Related]
60. hNUDC promotes the cell proliferation and differentiation in a leukemic cell line via activation of the thrombopoietin receptor (Mpl).
Tang YS; Zhang YP; Xu P
Leukemia; 2008 May; 22(5):1018-25. PubMed ID: 18288130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
